5248042026-07-012026-09-305248042026-09-305248042026-03-315248042026-04-012026-09-305248042026-07-012026-09-30in-capmkt:OtherExpenses1Member5248042026-04-012026-09-30in-capmkt:OtherExpenses1Member5248042026-09-30OtherNoncurrentFinancialAssetsDomain15248042026-09-30OtherNoncurrentAssetsDomain15248042026-09-30OtherNoncurrentAssetsDomain25248042026-09-30OtherCurrentFinancialAssetsDomain15248042026-09-30OtherCurrentAssetsDomain15248042026-09-30OtherNoncurrentFinancialLiabilitiesDomain15248042026-09-30OtherNoncurrentFinancialLiabilitiesDomain25248042026-09-30OtherNoncurrentLiabilitiesDomain15248042026-09-30OtherCurrentFinancialLiabilitiesDomain15248042026-09-30OtherCurrentFinancialLiabilitiesDomain25248042026-09-30OtherCurrentLiabilitiesDomain15248042026-07-012026-09-30ItemsThatWillNotBeReclassifiedToProfitAndLoss15248042026-07-012026-09-30ItemsThatWillNotBeReclassifiedToProfitAndLoss25248042026-07-012026-09-30ItemsThatWillNotBeReclassifiedToProfitAndLoss35248042026-04-012026-09-30ItemsThatWillNotBeReclassifiedToProfitAndLoss15248042026-04-012026-09-30ItemsThatWillNotBeReclassifiedToProfitAndLoss25248042026-04-012026-09-30ItemsThatWillNotBeReclassifiedToProfitAndLoss35248042026-07-012026-09-30ItemsThatWillBeReclassifiedToProfitAndLoss15248042026-07-012026-09-30ItemsThatWillBeReclassifiedToProfitAndLoss25248042026-07-012026-09-30ItemsThatWillBeReclassifiedToProfitAndLoss35248042026-04-012026-09-30ItemsThatWillBeReclassifiedToProfitAndLoss15248042026-04-012026-09-30ItemsThatWillBeReclassifiedToProfitAndLoss25248042026-04-012026-09-30ItemsThatWillBeReclassifiedToProfitAndLoss3iso4217:INRiso4217:INRxbrli:shares524804AUROPHARMANOTLISTEDINE406A01037AUROBINDO PHARMA LIMITEDMain BoardEquity2026-04-012027-03-312026-11-042026-10-26INRMillionsQuarterlySecond quarterSingle segmentPharmaceutical products2026-11-0416:15:002026-11-0418:00:00trueCash Flow IndirectNot applicable2026-07-012026-09-30UnauditedConsolidated1026329000001682200000104315100000298028000009137600000893000000165855000001022100000531150000024656500000874090000001690610000001690610000050857000005526000005638300000011267800000000-294000001123840000020292000001326760000011260800000-2240000013290000000-22400000575400000119.5719.570019.5719.571.The above unaudited consolidated financial results of Aurobindo Pharma Limited ("the Company") including its subsidiaries (collectively known as "the Group") and its associates and joint ventures have been prepared in accordance with the Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013 ("the Act"), read with the relevant rules issued thereunder and other accounting principles generally accepted in India and in terms of Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. <br /> 2.The above unaudited consolidated financial results have been prepared in accordance with principles and procedures as set out in the Ind AS 110 on "Consolidated financial statements" and Ind AS 28 on "Investments in Associates and Joint ventures" notified under Section 133 of the Act and Companies (Indian Accounting Standards) Rules, 2015, as amended. <br /> 3.The above unaudited consolidated financial results of the Group as reviewed by the Audit Committee has been approved by the Board of Directors at its meeting held on November 04, 2026. The results for the quarter and half year ended September 30, 2026 has been reviewed by our statutory auditors. The statutory auditors of the Company have issued an unmodified opinion in respect of the limited review for the quarter and half year ended September 30, 2026. <br /> 4.The Group operates in only one reportable segment viz., 'Pharmaceuticals ' in accordance with Ind AS 108, "Operating Segment". <br /> 5.During the half year ended September 30, 2026: <br /> i) The Company, incorporated a step down subsidiary, Arrow Pharma Production SAS, France through Agile Pharma B.V., Netherlands a wholly owned subsidiary of the Company w.e.f. May 21, 2026. <br /> ii) The Company invested Rs. 5.2 million to acquire 26% stake in Swarnaakshu Solar Power Private Limited, India making it an associate company w.e.f. June 25, 2026. <br /> iii) The Company, incorporated a step down subsidiary, PT Auro Pharm Indonesia through PT Aurogen Pharma Indonesia, a wholly owned subsidiary of the Company w.e.f. July 01, 2026. <br /> iv) The Company, incorporated a subsidiary, Auropharm Overseas Limited w.e.f. Aug 13, 2026. <br /> v) The Company, incorporated a step down subsidiary, A1 Biochem USA INC through A1 Biochem Labs (India) Private Limited, a wholly owned subsidiary of the Company w.e.f. Aug 26, 2026. <br /> vi) The Company, incorporated a step down subsidiary, Avogent Lifesciences Private Limited through Apitoria Pharma Private Limited, a wholly owned subsidiary of the Company w.e.f. Aug 31, 2026. <br /> vii) The Group invested Rs. 165.0 million to acquire stake in Garuda Renewables Private limited, India making it an associate company w.e.f. July 29, 2026. <br /> 6.On July 30, 2025, the Company through it's wholly owned subsidiary, Aurobindo Pharma USA, Inc. entered into a definitive agreement to acquire 100% membership interest in Lannett Company LLC. <br /> <br /> On June 29, 2026 ('Acquisition date') the Company pursuant to above membership purchase agreement completed the acquisition of 100% membership interest in Lannett Company LLC along with its subsidiaries (Silarx Pharmaceuticals Inc, Kremers Urban Pharmaceuticals Inc and Cody Laboratories Inc) for a purchase consideration of Rs. 23,218.3 million (USD 245.7 million) upon satisfaction of customary closing conditions and receipt of the necessary regulatory approvals and has been consolidated with effect from that date. Hence, the results for the quarter and half year ended September 30, 2026, are not comparable to the earlier periods presented. The transaction was accounted for in accordance with Ind AS 103 (Business Combinations), and the initial accounting has been provisionally determined. The group recognised Rs.18,615.7 million (USD 197.0 million) towards the fair value of net assets acquired and Rs. 4,602.7 million (USD 48.7 million) towards Goodwill. <br /> <br /> 7.The Board of Directors of the Parent Company at its meeting held on April 06, 2026 approved the transfer of domestic branded generic pharmaceutical formulations products business on a going concern basis through a Business Transfer Agreement (“BTA”) to Auropharm Limited (previously known as Auro Pharma Limited), a wholly owned subsidiary of the Company on a going concern basis w.e.f April 01, 2026. Accordingly, the net assets of the business have been transferred at the consideration of Rs. 1,432.1 million to Auropharm Limited. Since the transaction is with the wholly owned subsidiary of the Company, there is no impact on the unaudited consolidated financial statements. <br /> 8.Exceptional item: <br /> a) For the half year ended September 30, 2026 includes acquisition and related costs of Rs. 401.8 million (USD 4.3 million) in relation to the acquisition of 100% membership interest of Lannett Company LLC. <br /> <br /> b) During the year ended March 31, 2026, the Government of India consolidated 29 existing labour legislations into a unified framework comprising four labour codes as follows: Code on Wages, 2019, Code on Social Security, 2020, Industrial Relations Code, 2020 and Occupational Safety, Health and Working Conditions Code, 2020 (collectively referred to as the "New Labour Codes"). The New Labour Codes are effective from November 21, 2025 and introduce changes that include, among other things, setting a uniform definition of wages. The Government is in the process of issuing related rules. The New Labour Codes have implications on employee benefits including gratuity, leave encashment, and other related obligations. The Company assessed the implications of the New Labour Codes and recognized an incremental cost of Rs. 653.3 million during the year ended March 31, 2026. <br /> <br /> 9.The Board of Directors of Parent Company at their meeting held on April 06, 2026, approved buyback of 5,423,728 fully paid-up equity shares of face value of Rs. 1 each (representing 0.93% of the total number of equity shares of the parent company) for an aggregate value not exceeding Rs. 8,000.0 million (buyback size) (excluding transaction cost) at a maximum buyback price of Rs. 1,475 per equity share. Upon completion of the buyback, the parent company extinguished the equity shares in compliance with applicable rules and regulations. <br /> Consequently, the paid-up equity share capital has been reduced by Rs. 5.4 million. The aggregate amount paid for buyback is Rs. 8,058 million including related expenses. <br /> 10.During the quarter , Apitoria Pharma Private Limited (a wholly owned subsidiary of the Company), completed the acquisition of A1 Biochem Labs (India) Private Limited (“A1 Biochem Labs”) for a consideration of Rs.28.5 million. A1 Biochem Labs acquired the business of A1 Biochem Research (India) Private Limited for a consideration of Rs.200.0 million on a slump sale basis. Further on August 26, 2026, the Company incorporated A1 Biochem USA Inc. as a step-down subsidiary through A1 Biochem Labs (India) Private Limited. <br /> Subsequent to the quarter-end, as on October 1, 2026, A1 Biochem USA Inc acquired Membership Interest in A1 Biochem Labs LLC, USA for a consideration of Rs.1,462.1 million. <br /> <br /> 11.During the half year, Aurobindo Pharma USA, Inc., a wholly owned subsidiary of the Company recorded net loss on derecognition of lease receivable of Rs. 432.6 million (USD 4.5 million) which is included under the head “Other expenses”. <br /> 12.a. On July 27, 2026, Curateq Biologics Private Limited (wholly owned subsidiary of the Company) submitted the Scheme of Amalgamation by way of merger of Auro Vaccines Private Limited (Transferor Company) with Curateq Biologics Private Limited (Transferee Company) (the 'Applicant Companies') to the National Company Law Tribunal ('NCLT') for approval. Subsequently, on August 18, 2026, the Applicant Companies received an order from the NCLT dispensing with the requirement to convene meetings of their equity shareholders, secured and unsecured creditors, and Compulsorily Convertible Debenture (CCD) holders. <br /> <br /> b. On September 18, 2026, Eugia Pharma Specialities Limited (wholly owned subsidiary of the Company) submitted the Scheme of Amalgamation by way of merger of Eugia SEZ Private Limited and Eugia Steriles Private Limited (Transferor Company) with Eugia Pharma Specialities Limited (Transferee Company) (the 'Applicant Companies') to the National Company Law Tribunal ('NCLT') for approval. Subsequently, on October 9, 2026, the Company received an order from the NCLT directing it to convene meetings of its unsecured trade creditors, while dispensing with the requirement to convene a meeting of the Applicant Company’s equity shareholders. <br /> <br /> Pending regulatory approvals, no impact has been given in the results for the above. <br /> <br /> 13.The Board of Directors at their meeting held on November 4, 2026 declared an interim dividend of Rs. 7 per equity share (Face value Rs. 1). <br /> 2026-04-012026-09-30UnauditedConsolidated19413640000043245000001984609000005874680000018455400000-1099300000313870000002038700000101797000004627840000016598670000032474200000-4018000003207240000011185800000-71690000010468900000021603500000000-447000002155880000015605000002311930000021586500000-2770000023147000000-27700000575400000137.5237.520037.5237.52Other Expenses24656500000Other Expenses46278400000152916000000348706000000126862000003404640000014505000000014134000001835500000100000725000004271500000617960000015588700000575040000027795630000013124420000028650000075435300000623151000003717760000018310000022690000001776666000002000000003047580000033958660000000617542900000575400000393423600000393999000000-190000003939800000009819300000000515690000014976200000376910000030159000000513000000026891200000725182000001563600000573603000005892390000048253900000179696000000763870000043981000004938900000019667170000000223562900000617542900000Other financial assets4271500000Other non-current assets3837600000Non- current tax assets1912800000Other financial assets2269000000Other current assets30475800000Lease liabilities2732300000Other financial liabilities2424600000Other non-current liabilities5130000000Lease liabilities1227900000Other financial liabilities47026000000Other current liabilities76387000001930300000-37445000009496000000-168630000002062900000001383900000049050000001017970000005837000000-25553000000-60100000128000002660800000000-3483000000-19000000064935000003856590000000057345000000328314000000201397000000-6963200000000056570000014301000000000225080000000000000000001280000024147000000-10287000000-370221000009030000000080580000000001130770000060025000001477200000400000181640000000-5956500000-10147200000447700000-96995000007191400000062214500000Re-measurement of defined employee benefit liability-49500000Equity investments through other comprehensive income – net change in fair value39900000Income-tax relating to items that will not be reclassified to profit or loss2900000-6700000Re-measurement of defined employee benefit liability-45900000Equity investments through other comprehensive income – net change in fair value-41200000Income-tax relating to items that will not be reclassified to profit or loss20400000-6670000000Exchange differences on translating the financial statements of foreign operations1977500000Fair value change on derivatives designated as cash flow hedge (net)78000000Income-tax on items that will be reclassified subsequently to profit or loss-196000002035900000Exchange differences on translating the financial statements of foreign operations1568800000Fair value change on derivatives designated as cash flow hedge (net)78000000Income-tax on items that will be reclassified subsequently to profit or loss-1960000016272000000020292000001560500000